Avita Medical Ltd (RCEL)

[Fmello]

Japan approval has been held up due to the Wuhan virus but approval is still expected this year. Also, the pending Japan application application was not solely for burn wounds but for all forms of skin repair, including vitiligo, diabetic foot ulcers and venous leg ulcers.

“The number of patients suffering from chronic wounds and decubitus ulcers is increasing in Japan due to aging. Japan is also planning for the Tokyo Olympic Games in 2020 and must be prepared for major disasters such as a large earthquake. We are very proud to add the RECELL System to our product lineup,” said Mr. Kiyoshi Takei, President of COSMOTEC. “With over 30 years since our foundation, COSMOTEC has been doing business in 90-100% of high acute care hospitals in Japan in the fields of cardiac surgery, vascular surgery, and wound care. As a member of the M3 Group, we can deliver the RECELL System's benefits to at least 90% of Japanese plastic surgeons and dermatologists through the portal site 'm3.com.' With this opportunity, we would like to contribute to the advancement of burn injury and wound care in Japan.”

"Japan is the second largest healthcare market in the world and represents a valuable market for the RECELL System with more than 6,000 patients with severe burns treated in hospitals each year. Over two million people in Japan are estimated to have vitiligo, a disease that causes the loss of skin color in blotches and can affect the skin on any part of a patient’s body."